Skip to content
NASDAQ · SERVICES-MEDICAL LABORATORIES · MID CAP

Fulgent Genetics, Inc. FLGT

12 fiscal years on record · USD · FY2025 reported · SEC filings only
$322.7M
▲ 13.8% YoY
$-60.5M
$-124.2M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Fulgent Genetics, Inc. is a technology-based company that operates a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business develops product candidates for treating a broad range of cancers using a nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates five CLIA-certified and CAP-accredited laboratories across the United States. As of December 31, 2025, the company had 1,315 full-time employees in its laboratory services business and 29 full-time employees in its therapeutic development business. One customer accounted for $70.8 million, or 22% of total revenue, in 2025. The company was incorporated in Delaware on May 13, 2016, as the holding company for its subsidiaries, including Fulgent Therapeutics LLC, which was initially formed in June 2011.

Written from the business description in Fulgent Genetics, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 27 February 2026. Every sentence was checked against that document before publication.

Growth

USD 322.7M
Revenue, FY2025 · full 12-year series below
Revenue $M Net income $M
FY2025 · Revenue 322.7 · Net income -60.5
400M800M-100M-200M
20142017202020232025
Compound annual growth
−19.5%
−5.2%
+42.2%
−47.3%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −5.2% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−19 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -28.2% · Net -19.1%
20%40%60%-100%-200%-300%
201420192025
ROE
FY2025 · ROE -5.4%
20%40%60%-100%-200%
201420192025
Three returns, three denominators.

Each USD of equity lost 5 cents this year.

Cash & shareholders

USD 10.9M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -124.2
200M400M-50M-100M
201420192025
Net buybacks $M Dividends $M
FY2025 · Dividends · · Net buybacks 10.9
30M60M-100M-200M
201920202022202320242025

USD 10.9M in buybacks went back to shareholders in a year without profit.

Total assetsUSD 1.2B
EquityUSD 1.1B
CashUSD 50.2M
Current ratio6.48×

Equity funds 92% of total assets.

The 12-year record

12 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
FLGT, 12-year financial record
Metric 202520242023202220212020201920182017201620152014
Revenue $B0.30.30.30.61.00.40.00.00.00.00.00.0
Operating income $B−0.1−0.1−0.20.20.70.3−0.0−0.0−0.00.0−0.0−0.0
EBITDA $B−0.1−0.0−0.20.20.70.30.0−0.0−0.0◌◌◌
Income tax $B−0.0−0.00.00.00.20.10.00.0−0.00.00.00.0
Net income $B−0.1−0.0−0.20.10.50.2−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.1−0.00.00.20.50.10.0−0.0−0.00.0−0.0−0.0
EPS, diluted $◌◌◌◌◌◌◌◌◌◌◌◌
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend————————————
ROE %−5.4−3.8−14.011.858.765.7−0.6−10.6−4.6−17.9−243.5−254.3
Shares out B0.030.030.030.030.030.030.020.020.020.02◌◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 46 reconciliationsAUDITED

Reconciled in 12 of the 12 fiscal years we could check. 16 checks were skipped: the balance sheet is not tagged before 2015. Seven checks were skipped: the share count is not tagged before 2014. Seven checks were skipped: revenue is not tagged before 2014.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityServices-Medical Laboratories
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2014

Share this section

Download image